Denali Therapeutics, which is developing treatments for neurodegenerative diseases, announced terms for its IPO on Monday.
The San Francisco, CA-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. Insiders intend to purchase $50 million worth of shares in the offering. At the midpoint of the proposed range, Denali Therapeutics would command a fully diluted market value of $1.6 billion.
Denali Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol DNLI. Goldman Sachs, Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal. It is expected to price during the week of December 4, 2017.
